A dual‐specific anti‐IGF‐1/IGF‐2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Cancer

• Publication date

  2015-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.29588PMID 25924852PMCID PMC4978514
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A new bispecific antibody targeting non-overlapping epitopes on IGF2: design, in vitro characterization and pharmacokinetics in macaques.

  2014cited by this paper
• Heterogeneity of neuroblastoma cell lines in insulin‐like growth factor 1 receptor/Akt pathway‐mediated cell proliferative responses

  2013cited by this paper
• Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

  2013cited by this paper
• A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.

  2013cited by this paper
• Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy

  2013cited by this paper
• Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro

  2013cited by this paper
• New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome

  2012cited by this paper
• Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology.

  2012cited by this paper
• Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

  2012cited by this paper
• Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.

  2012cited by this paper
• Antibody-based therapeutics against components of the IGF system

  2012cited by this paper
• Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?

  2012cited by this paper
• Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls

  2012cited by this paper
• Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

  2012cited by this paper
• Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2

  2011cited by this paper
• Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.

  2011cited by this paper
• Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

  2011influential reference
• Insulin receptor and cancer.

  2011cited by this paper
• Initial testing (stage 1) of the IGF‐1 receptor inhibitor BMS‐754807 by the pediatric preclinical testing program

  2011cited by this paper
• Human Monoclonal Antibody Fragments Binding to Insulin-like Growth Factors I and II with Picomolar Affinity

  2011cited by this paper
• Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

  2011cited by this paper
• Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing's and Osteogenic Sarcoma Models

  2011cited by this paper
• Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma.

  2010influential reference
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines In vitro and In vivo

  2010cited by this paper
• Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program

  2010cited by this paper
• Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer

  2010influential reference
• BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

  2009influential reference
• Clinical development of inhibitors of the insulin-like growth factor receptor in oncology.

  2009cited by this paper
• The role of IGF-1R in pediatric malignancies.

  2009cited by this paper
• IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons

  2008cited by this paper
• Insulin and insulin-like growth factor signalling in neoplasia

  2008cited by this paper
• Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

  2008cited by this paper
• The role of the IGF system in cancer growth and metastasis: overview and recent insights.

  2007cited by this paper
• Down-Regulation of Insulin-Like Growth Factor I Receptor Activity by NVP-AEW541 Has an Antitumor Effect on Neuroblastoma Cells In vitro and In vivo

  2006influential reference
• Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone.

  2006influential reference
• Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function

  2006cited by this paper
• Insulin and Insulin-Like Growth Factor I Receptors: Similarities and Differences in Signal Transduction

  2004cited by this paper
• Insulin-like growth factor-I signaling in human neuroblastoma cells

  2004cited by this paper
• Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

  2004cited by this paper
• Signals transduced via insulin-like growth factor I receptor (IGF(R)) mediate resistance to retinoic acid-induced cell growth arrest in a human neuroblastoma cell line.

  1994cited by this paper
• Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor.

  1990influential reference

• Reciprocal regulation between B lymphoma Mo-MLV insertion region 1 homolog and type I insulin-like growth factor receptor in pemetrexed-resistant lung cancer cells

  2025cites this paper
• Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma

  2024cites this paper
• Therapeutic Monoclonal Antibodies against Cancer: Present and Future

  2023cites this paper
• Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma.

  2023cites this paper
• SuperDendrix algorithm integrates genetic dependencies and genomic alterations across pathways and cancer types

  2022cites this paper
• An insulin growth factor-I/II-neutralizing monoclonal antibody in combination with epidermal growth factor receptor inhibitors potently inhibits tumor cell growth

  2022cites this paper
• Insulin-like growth factors: Ligands, binding proteins, and receptors

  2021influential citation
• Advances in pharmacotherapy for neuroblastoma

  2021cites this paper
• Proteomic investigation of Cbl and Cbl-b in neuroblastoma cell differentiation highlights roles for SHP-2 and CDK16

  2021cites this paper
• The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives

  2020cites this paper
• Integrating genetic dependencies and genomic alterations across pathways and cancer types

  2020cites this paper
• Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing

  2019cites this paper
• Nanomedicine-combined immunotherapy for cancer.

  2019cites this paper
• pH-sensitive loaded retinal/indocyanine green micelles as an "all-in-one" theranostic agent for multi-modal imaging in vivo guided cellular senescence-photothermal synergistic therapy.

  2019cites this paper
• Nano-loaded natural killer cells as carriers of indocyanine green for synergetic cancer immunotherapy and phototherapy

  2019cites this paper
• Screening and expressing HIV‐1 specific antibody fragments in Saccharomyces cerevisiae

  2018cites this paper
• A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells

  2018cites this paper
• New developments in immunotherapy for pediatric solid tumors

  2017cites this paper
• CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression

  2017cites this paper
• RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma

  2017cites this paper
• Rapamycin: A promising agent to treat cancer pain?

  2016cites this paper
• Immunotherapy of Childhood Sarcomas

  2015cites this paper